SynthesisJournal of neuro-oncology2013
Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.
Synthesis in Journal of neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Ultra-High-Field MRI in the Diagnosis and Management of Gliomas: A Systematic Review.Frontiers in neurology · 2022Pooled it
- Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis.Molecular neurobiology · 2016Pooled it
- Prognostic Role of microRNA-21 Expression in Brain Tumors: a Meta-analysis.Molecular neurobiology · 2016Pooled it
- CRYM suppresses glioblastoma progression by inhibiting the TGFβ1/Smad-EMT signaling pathway.Journal of neuro-oncology · 2026Article
- Ensemble Machine Learning Approaches Predict Survival in Lower-Grade Glioma Based on Glycosphingolipid Gene Expression and Metabolic Modeling.Computational and structural biotechnology journal · 2026Article
- Role of dynamic contrast-enhanced and dynamic susceptibility contrast imaging in evaluating the biological features of glioma.Quantitative imaging in medicine and surgery · 2025Article
- "Aiming at a moving target"-The daily life experiences of adolescents and young adults with a low-grade glioma.Neuro-oncology practice · 2025Article
- Modernizing Neuro-Oncology: The Impact of Imaging, Liquid Biopsies, and AI on Diagnosis and Treatment.International journal of molecular sciences · 2025Review
- Integrative multi-omic profiling of the neoantigen landscape of glioblastoma for the development of therapeutic vaccines reveals vast heterogeneity in immunogenic signatures.Frontiers in oncology · 2025Article
- Mechanism analysis and targeted therapy of IDH gene mutation in glioma.American journal of cancer research · 2025Review
- DNA methylation heterogeneity attributable to a complex tumor immune microenvironment prompts prognostic risk in glioma.Epigenetics · 2024Article
- Ultra-high b-value DWI accurately identifies isocitrate dehydrogenase genotypes and tumor subtypes of adult-type diffuse gliomas.European radiology · 2024Article
- Molecular profile and clinical features of patients with gliomas using a broad targeted next generation-sequencing panel.Oncology letters · 2023Article
- High LYRM4-AS1 predicts poor prognosis in patients with glioma and correlates with immune infiltration.PeerJ · 2023Article
- Long non-coding RNA in glioma: novel genetic players in temozolomide resistance.Animal cells and systems · 2023Review
- Glioma features and seizure control during long-term follow-up.Epilepsy & behavior reports · 2023Article
- Basement-Membrane-Related Gene Signature Predicts Prognosis in WHO Grade II/III Gliomas.Genes · 2022Article
- T2-fluid-attenuated inversion recovery mismatch sign in lower grade gliomas: correlation with pathological and molecular findings.Brain tumor pathology · 2022Article
- Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients.European radiology · 2022Article
- Prognostic and Predictive Biomarkers in Gliomas.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in the gene encoding isocitrate dehydrogenase (IDH) have been identified in approximately 65-90 % of low-grade gliomas (LGGs). Various studies examining the relationship between IDH mutation with the clinical outcome in patients with LGGs have yielded inconclusive results. The purpose of the present meta-analysis of literature is to determine this effect. We conducted a meta-analysis of 10 studies (937 patients) that evaluated the correlation between IDH mutation and overall survival (OS). For the quantitative aggregation of the survival results, the IDH mutation effect was measured by hazard ratio (HR). Overall, the pooled HR was 0.585 (95 % CI, 0.376-0.911, p = 0.025, random effect model) for patients with IDH mutation vs patients without IDH mutation. IDH mutation was associated with better overall survival of LGGs. At least this trend was observed in our analysis.
Indexed as
Identifiers
23504258What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.